Cartwright William S
George Mason University, Fairfax, VA 22030, USA.
J Subst Abuse Treat. 2008 Mar;34(2):224-33. doi: 10.1016/j.jsat.2007.04.003. Epub 2007 Jun 27.
This article examines costs as they relate to the financial costs of providing drug abuse treatment in private and public health plans, costs to society relating to drug abuse, and many smaller costing studies of various stakeholders in the health care system. A bibliography is developed from searches across PubMed, Web of Science, and other bibliographic sources. The review indicates that a wide collection of cost findings is available to policy makers. For example, the financial aspects of health plans have been dominated by considerations of actuarial costs of parity for drug abuse treatment. Cost-of-illness methods have been developed and extended to drug abuse costing to measure the national level of burden and are important to the economic evaluation of interventions at the program level. Costing is done in many small and focused studies, reflecting the interests of different stakeholders in the health care system. For costs in programs and health plans, as well as cost offsets of the impact of substance abuse treatment on medical expenditures, findings are surprisingly important to policy makers. Maintaining ongoing research that is highly policy relevant from the point of view of health services, more is needed on costing concepts and measurement applications.
本文探讨了与在私人和公共卫生计划中提供药物滥用治疗的财务成本相关的成本、与药物滥用相关的社会成本，以及医疗保健系统中各利益相关方的许多小型成本研究。通过对PubMed、科学网和其他文献来源进行检索，编制了一份参考文献目录。该综述表明，政策制定者可以获得大量的成本研究结果。例如，卫生计划的财务方面一直以药物滥用治疗平价的精算成本考量为主。疾病成本法已得到发展并扩展到药物滥用成本核算，以衡量国家层面的负担水平，并且对于项目层面干预措施的经济评估很重要。成本核算在许多小型且有针对性的研究中进行，反映了医疗保健系统中不同利益相关方的利益。对于项目和卫生计划中的成本，以及药物滥用治疗对医疗支出影响的成本抵消，研究结果对政策制定者来说出人意料地重要。从卫生服务的角度来看，需要开展更多与政策高度相关的持续研究，在成本核算概念和测量应用方面还有更多工作要做。
